NCT05913388View on ClinicalTrials.gov

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

February 28, 2030

Conditions
Metastatic MelanomaHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

GB1211

Administered orally twice daily at 100mg.

DRUG

Pembrolizumab

Administered at a fixed dose of 200 mg every 3 weeks intravenously.

DRUG

Placebo

Administered orally twice daily at 100mg.

Trial Locations (1)

97213

RECRUITING

Providence Portland Medical Center, Portland

Sponsors

Collaborators (1)

Galecto Biotech AB
All Listed Sponsors
collaborator

Providence Cancer Center

UNKNOWN

collaborator

Providence Cancer Center, Earle A. Chiles Research Institute

OTHER

collaborator

Galecto Biotech AB

INDUSTRY

lead

Providence Health & Services

OTHER

NCT05913388 - GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter